Based on your commentary at that time around guidance framing though, would this imply the business was running up positive double-digits in December Christmas based on reported North American Local growth of plus 8% year-over-year
In some cases, GLP-1 produced by the body is not enough or the brain cannot sense it, hence the production of synthetic GLP-1 medication like Semaglutide
Lower concentrations (1-2 mg/mL) mean larger injection volumes, which is slightly less comfortable but significantly easier to measure accurately

Real-World Examples: 250-Pound Person: Average loss: 56 pounds (22.5%) Final weight: 194 pounds Timeline: 18-20 months 200-Pound Person: Average loss: 45 pounds (22.5%) Final weight: 155 pounds Timeline: 18-20 months 300-Pound Person: Average loss: 67 pounds (22.5%) Final weight: 233 pounds Timeline: 20-24 months Dosing Schedule: Standard Escalation: Weeks 1-4: 2.5 mg weekly (starting dose) Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly Weeks 13-16: 10 mg weekly (if tolerating well) Weeks 17-20: 12.5 mg weekly (if needed) Week 21+: 15 mg weekly (maximum dose for weight loss) Flexible Dosing: Not everyone needs maximum 15 mg dose Many achieve excellent results at 10 mg Provider adjusts based on results and tolerance Can stay at effective dose rather than pushing to maximum Side Effects: Most Common: Nausea: 30-37% (lower than semaglutide despite higher potency) Diarrhea: 19-23% Vomiting: 9-17% Constipation: 10-17% Abdominal discomfort: 8-11% Interesting Finding: Despite being more potent, tirzepatide causes less nausea and vomiting than semaglutide

[1] [2] Tablets must be swallowed whole and not split, crushed or chewed
This dual action is the main reason why Mounjaro tends to outperform Wegovy in clinical trials